Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917–27.
Article CAS PubMed PubMed Central Google Scholar
Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851–7.
Article CAS PubMed Google Scholar
Minciacchi VR, Kumar R, Krause DS. Chronic myeloid leukemia: a model disease of the past. Cells. 2021;10:117.
Article PubMed PubMed Central Google Scholar
Braun TP, Eide CA, Druker BJ. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell. 2020;37:530–42.
Article CAS PubMed PubMed Central Google Scholar
Mitchell R, Hopcroft LEM, Baquero P, Allan EK, Hewit K, James D, et al. Targeting BCR-ABL-independent TKI resistance in chronic myeloid leukemia by mTOR and autophagy inhibition. J Natl Cancer Inst. 2018;110:467–78.
Article CAS PubMed Google Scholar
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783–96.
Article CAS PubMed Google Scholar
Bavaro L, Martelli M, Cavo M, Soverini S. Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: an update. Int J Mol Sci. 2019;20:6141.
Article CAS PubMed Central Google Scholar
Chu S, McDonald T, Lin A, Chakraborty S, Huang Q, Snyder DS, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 2011;118:5565–72.
Article CAS PubMed PubMed Central Google Scholar
Hashiyama M, Iwama A, Ohshiro K, Kurozumi K, Yasunaga K, Shimizu Y, et al. Predominant expression of a receptor tyrosine kinase, TIE, in hematopoietic stem cells and B cells. Blood. 1996;87:93–101.
Article CAS PubMed Google Scholar
Teufel M, Seidel H, Kochert K, Meinhardt G, Finn RS, Llovet JM, et al. Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma. Gastroenterology. 2019;156:1731–41.
Article CAS PubMed Google Scholar
Fagiani E, Lorentz P, Kopfstein L, Christofori G. Angiopoietin-1 and -2 exert antagonistic functions in tumor angiogenesis, yet both induce lymphangiogenesis. Cancer Res. 2011;71:5717–27.
Article CAS PubMed Google Scholar
Liu XH, Bai CG, Yuan Y, Gong DJ, Huang SD. Angiopoietin-1 targeted RNA interference suppresses angiogenesis and tumor growth of esophageal cancer. World J Gastroenterol. 2008;14:1575–81.
Article CAS PubMed PubMed Central Google Scholar
Torimura T, Ueno T, Kin M, Harada R, Taniguchi E, Nakamura T, et al. Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. J Hepatol. 2004;40:799–807.
Article CAS PubMed Google Scholar
Cheng CL, Hou HA, Jhuang JY, Lin CW, Chen CY, Tang JL, et al. High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes. Br J Cancer. 2011;105:975–82.
Article CAS PubMed PubMed Central Google Scholar
Lee CY, Tien HF, Hu CY, Chou WC, Lin LI. Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia. Br J Cancer. 2007;97:877–82.
Article CAS PubMed PubMed Central Google Scholar
Schliemann C, Bieker R, Padro T, Kessler T, Hintelmann H, Buchner T, et al. Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia. Haematologica. 2006;91:1203–11.
Grenga I, Kwilas AR, Donahue RN, Farsaci B, Hodge JW. Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack. J Immunother Cancer. 2015;3:52.
Article PubMed PubMed Central Google Scholar
Atesoglu EB, Tarkun P, Mehtap O, Demirsoy ET, Atalay F, Maden M, et al. Serum angiopoietin levels are different in acute and chronic myeloid neoplasms: angiopoietins do not only regulate tumor angiogenesis. Indian J Hematol Blood Transfus. 2016;32:162–7.
Ichim CV. Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors. Stem Cells Transl Med. 2014;3:405–15.
Article CAS PubMed PubMed Central Google Scholar
Aranda-Tavio H, Recio C, Martin-Acosta P, Guerra-Rodriguez M, Brito-Casillas Y, Blanco R, et al. JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia. Biomed Pharmacother. 2021;144:112330.
Article CAS PubMed Google Scholar
Huang H, Bhat A, Woodnutt G, Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer. 2010;10:575–85.
Article CAS PubMed Google Scholar
Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004;118:149–61.
Article CAS PubMed Google Scholar
Parikh SM. Targeting Tie2 and the host vascular response in sepsis. Sci Transl Med. 2016;8:335fs339.
Tolomeo M, Meli M, Grimaudo S. STAT5 and STAT5 inhibitors in hematological malignancies. Anticancer Agents Med Chem. 2019;19:2036–46.
Article CAS PubMed Google Scholar
Gleixner KV, Schneeweiss M, Eisenwort G, Berger D, Herrmann H, Blatt K, et al. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. Haematologica. 2017;102:1519–29.
Article CAS PubMed PubMed Central Google Scholar
Dong B, Liang Z, Chen Z, Li B, Zheng L, Yang J, et al. Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation. Sci China Life Sci. 2018;61:999–1009.
Article CAS PubMed Google Scholar
Pinz S, Unser S, Rascle A. Signal transducer and activator of transcription STAT5 is recruited to c-Myc super-enhancer. BMC Mol Biol. 2016;17:10.
Article PubMed PubMed Central Google Scholar
Warsch W, Grundschober E, Sexl V. Adding a new facet to STAT5 in CML: multitasking for leukemic cells. Cell Cycle. 2013;12:1813–4.
Article CAS PubMed PubMed Central Google Scholar
Bibi S, Arslanhan MD, Langenfeld F, Jeanningros S, Cerny-Reiterer S, Hadzijusufovic E, et al. Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy. Haematologica. 2014;99:417–29.
Article CAS PubMed PubMed Central Google Scholar
Juen L, Brachet-Botineau M, Parmenon C, Bourgeais J, Herault O, Gouilleux F, et al. New inhibitor targeting signal transducer and activator of transcription 5 (STAT5) signaling in myeloid leukemias. J Med Chem. 2017;60:6119–36.
Article CAS PubMed Google Scholar
Jiang X, Cheng Y, Hu C, Zhang A, Ren Y, Xu X. MicroRNA-221 sensitizes chronic myeloid leukemia cells to imatinib by targeting STAT5. Leuk Lymphoma. 2019;60:1709–20.
Article CAS PubMed Google Scholar
Orlova A, Wagner C, de Araujo ED, Bajusz D, Neubauer HA, Herling M, et al. Direct targeting options for STAT3 and STAT5 in cancer. Cancers. 2019;11:1930.
Article CAS PubMed Central Google Scholar
Mirmohammadsadegh A, Hassan M, Bardenheuer W, Marini A, Gustrau A, Nambiar S, et al. STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases. J Investig Dermatol. 2006;126:2272–80.
Article CAS PubMed Google Scholar
Ku M, Wall M, MacKinnon RN, Walkley CR, Purton LE, Tam C, et al. Src family kinases and their role in hematological malignancies. Leuk Lymphoma. 2015;56:577–86.
Article CAS PubMed Google Scholar
Okutani Y, Kitanaka A, Tanaka T, Kamano H, Ohnishi H, Kubota Y, et al. Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway. Oncogene. 2001;20:6643–50.
留言 (0)